Topic

Articles

The latest news about biologics facilities includes various expansions, new locations, and acquisitions in the bio/pharmaceutical space. 

Biologics Facilities Expand and Establish New  Locations in 2021

Catalent has acquired Promethera Biosciences’ cell therapy manufacturing subsidiary, which includes a 32,400 ft2 facility in Gosselies, Belgium.

Catalent to Acquire New Facility in Belgium for Commercial-Scale Plasmid DNA Manufacturing

Through the acquisition, Pfizer will have access to Amplyx’s lead compound, Fosmanogepix (APX001), an investigational asset under development for the treatment of invasive fungal infections.

Pfizer to Acquire Amplyx Pharmaceuticals

The acquisition, which is expected to be completed by the end of 2021, will give Thermo Fisher access to PPD’s drug development platform, patient recruitment capabilities, and laboratory services.

Thermo Fisher to Acquire PPD for $17.4 Billion

The deal will give Sanofi access to Tidal’s novel mRNA-based approach for in-vivo reprogramming of immune cells, which will expand Sanofi’s research capabilities in immuno-oncology and inflammatory diseases.

Sanofi to Acquire Tidal Therapeutics for $470 Million

Sterling Pharma Solutions has acquired ADC Biotechnology, a bioconjugation development services business specializing in antibody drug conjugates.

Sterling Pharma Solutions Confirms ADC Bio Acquisition

The business, which has been renamed Woodstock Sterile Solutions, will operate out of a single site in Woodstock, IL, and will support clinical- to commercial-stage formulation and manufacturing.

SK Capital Completes Acquisition of Catalent’s Blow-Fill-Seal CDMO

The acquisition will give Amgen access to Rodeo's 15-prostaglandin dehydrogenase program, which will strengthen its inflammation portfolio. 

Amgen to Acquire Rodeo Therapeutics for up to $721 Million

Romaco, supplier of processing and packaging equipment, has acquired STE Tecpharm, S. L., a Spanish manufacturer of processing technology. 

Romaco Acquires Spanish Processing Technology Manufacturer

Provider of iPSC-derived cells, media, and characterization services, Axol Bioscience, has signed a merger agreement with Censo Biotechnologies, a cell biology CRO.

Mergers and Acquisitions